AbbVie ditches license option for Harpoon's TriTAC multiple

Going forward, Harpoon said the TriTAC multiple myeloma program will remain exclusively within the company as it plans to complete an ongoing Phase 1 clinical trial with data to support the next phase of development.

Related Keywords

Julie Eastland , Haibo Wang , , Harpoon Therapeutics , Activating Construct , Hummingbird Bioscience ,